CTOs on the Move


 
Gevo has a mission to transform renewable energy into low carbon transportation fuels. This next generation of renewable premium gasoline, jet fuel and diesel fuel with the potential to achieve zero carbon emissions, addressing the market need of reducing greenhouse gas emissions with sustainable alternatives. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo`s products perform ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.gevo.com
  • 345 Inverness Drive South, Building C Suite 310
    Englewood, CO USA 80112
  • Phone: 303.858.8358

Executives

Name Title Contact Details
Paul Bloom
Chief Technology Officer and Chief Innovation Officer Profile

Similar Companies

Elevai Labs

ELEVAI LABS, INC. is a biotechnology company developing cutting-edge regenerative skincare applications. The company solves the unmet needs in the regenerative aesthetics space through a combination of cutting-edge science and next-generation consumer applications. Elevai Labs develops state-of-the-art topic anesthetic and pharmaceutical-grade skin care for the physician-dispensed market, with a focus on leveraging stem cell exosome technology.

Ziemer USA INC

Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncotelic

Mateon Therapeutics/Oncotelic is developing TGF-beta therapies and Apomorphine for Parkinson, ED, FSD. https://t.co/nReUVgPvhc. $OTLC

STAT PHARMACEUTICALS

STAT PHARMACEUTICALS is a Santee, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eyenovia

Eyenovia is a clinical stage, biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia`s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.